As more data has become available, scientists have taken a closer look at how GLP-1 receptor agonists affect the brain
In a retrospective cohort study including 7,044 patients with T2D, obesity (BMI 27 kg/m 2 ) and HFpEF, combination therapy with an SGLT2i and GLP-1 RA showed a lower risk of HF exacerbation, all-cause emergency department visits and new-onset kidney injury compared with patients only receiving SGLT2i
In short, people with type 1 diabetes, like so many others, still need the effective obesity treatment GLP-1s provide
22 and sp
GH proves essential for muscle restoration, tissue renewal, and inflammation reduction, making it fundamental for recovery
J Clin Endocrinol Metab, 91(3):799-805